BMJ Open Effect of ultrasonography surveillance in patients with liver cancer: a population-based longitudinal study

Jui-Kun Chiang,¹ Lin Chih-Wen,^{2,3} Yee-Hsin Kao⁴

To cite: Chiang J-K, Chih-Wen L, Kao Y-H. Effect of ultrasonography surveillance in patients with liver cancer: a population-based longitudinal study. *BMJ Open* 2017;7:e015936. doi:10.1136/bmjopen-2017-015936

► Prepublication history for this paper is available online. To view these files please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2017-015936>).

Received 12 January 2017
Revised 18 May 2017
Accepted 25 May 2017

CrossMark

¹Department of Family Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Dalin, Chiayi, Taiwan

²Department of Medical Imaging, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Dalin, Chiayi, Taiwan

³School of Medicine, Tzu Chi University, Hualien, Taiwan

⁴Department of Family Medicine, Tainan Municipal Hospital, Tainan, Taiwan

Correspondence to

Dr Yee-Hsin Kao;
m2200767@gmail.com

ABSTRACT

Objective Liver cancer is a growing global public health problem. Ultrasonography is an imaging tool widely used for the early diagnosis of liver cancer. However, the effect of ultrasonography surveillance (US) on the survival of patients with liver cancer is unknown. Therefore, this study examined the association between survival and US frequency during the 2 years preceding patients' liver cancer diagnosis.

Methods This population-based longitudinal study was conducted in Taiwan, a region with high liver cancer incidence, by using the National Health Insurance Research Database. We compared survival between patients who received US three times or more (≥ 3 group) and less than three times (< 3 group) during the 2 years preceding their liver cancer diagnosis, and identified the predictors for the ≥ 3 group.

Results This study enrolled 4621 patients with liver cancer who had died between 1997 and 2010. The median survival rate was higher in the ≥ 3 group (1.42 years) than in the < 3 group (0.51 years). Five-year survival probability was also significantly higher in the ≥ 3 group (14.4%) than in the < 3 group (7.7%). The multivariate logistic regression results showed that the three most common positive predictors for receiving three or more US sessions were indications of viral hepatitis, gallbladder diseases and kidney–urinary–bladder diseases; the most common negative predictors for receiving three or more US sessions were male sex and indications of abdominal pain.

Conclusion Patients with liver cancer who received US three times or more during the 2 years preceding their liver cancer diagnosis exhibited a higher 5-year survival probability.

INTRODUCTION

Liver cancer is a growing global public health problem and is the fifth and ninth most common cancer in men and women worldwide, respectively. Because of its poor outcome, it is also the second most common cause of cancer-related mortality, accounting for nearly 746 000 deaths worldwide in 2012.¹ Eastern and Southeastern Asia, including Taiwan, are regions with a particularly high incidence of liver cancer. In Taiwan, liver cancer has been the second leading cause of cancer-related mortality since 2004, and it accounted for 8116 (18.6%) of the 43 665

Strengths and limitations of this study

- This is a nationwide, population-based study that was conducted in Taiwan, a region that has a high incidence of liver cancer.
- We determined that patients' 5-year survival probability was significantly higher among those who had received three or more sessions of ultrasonography surveillance (US) (14.4%) than among those who received less than three sessions of US (7.7%).
- The survival results associated with patients receiving three or more sessions of US 2 years prior to their liver cancer diagnosis may be applicable to the general population in Taiwan because of the high incidence of liver cancer.
- No information on cancer stage was available in the dataset, and some crucial potentially confounding variables were also not available for performing statistical adjustment.
- The cause of death was not recorded in the insurance claims data, and therefore we cannot establish associations between liver cancer and mortality.

cancer deaths in 2012.² The known risk factors for liver cancer are viral infection (hepatitis B virus (HBV) and hepatitis C virus (HCV) infections), alcohol consumption and alpha toxins, diabetes, and metabolic (eg, non-alcoholic fatty liver disease (NAFLD) and hereditary haemochromatosis) and immune-related (eg, primary biliary cirrhosis and autoimmune hepatitis) diseases.³

One previous study reported that chronic HBV and HCV infections are the primary risk factors for liver cancer.⁴ To improve the effective control and treatment of viral hepatitis, two programmes have been implemented in Taiwan. The first is the mass vaccination programme targeted against HBV, which has considerably reduced the HBV carrier rate among children and adolescents and consequently reduced the incidence of childhood liver cancer in Taiwan.^{5–8} The second programme is a pilot programme initiated

in October 2003 by the Taiwanese Center for Disease Control, entitled ‘Strengthening of treatment for chronic hepatitis B and C under the National Health Insurance’. This programme has attempted to ensure that patients with chronic hepatitis B and C are registered, so that they can benefit from appropriate diagnosis, monitoring and treatment.⁹ Accordingly, the incidence of liver cancer significantly decreased by an average annual percentage of 1.1% from 2002 to 2012; during this same period, the 5-year relative survival rates for liver cancer were 52.0% for stage I, 2.9% for stage IV and 28.9% for all stages.¹⁰

A diagnosis of hepatocellular cancer is based on a combination of radiological, serological and histopathological criteria. Some studies have reported that alpha-fetoprotein determination lacks adequate sensitivity and specificity for effective surveillance^{11 12}; therefore, surveillance must be based on ultrasonography, which has a recommended screening interval of 6 months.^{13 14} A previous study reported that ultrasonography has a sensitivity of approximately 63% and a high specificity of approximately 85%–90% for the detection of early-stage liver cancer.¹² Moreover, ultrasonography is a non-invasive and safe method, is well accepted by patients and is relatively inexpensive.

Research has indicated that most patients with hepatocellular carcinoma have a low rate of survival. However, patients with early-stage hepatocellular carcinoma who receive potentially curative therapy exhibit considerably improved survival (5-year survival=40%–70%).¹⁵ One systemic review provided very-low-strength evidence about the effects of hepatocellular carcinoma screening on mortality in patients with chronic hepatitis.¹⁶ Nevertheless, regular surveillance with abdominal ultrasonography might facilitate the early detection of liver cancer, thus improving the survival of at-risk patients. This study therefore examined the effect of ultrasonography surveillance (US) on survival. Specifically, the association between patient survival and the frequency of US during the 2 years preceding liver cancer diagnosis was determined, and the predictors of receiving more US sessions were identified.

METHODS

Data source and patient identification

For this nationwide population-based study, we analysed the data from the National Health Insurance Research Database (NHIRD) of Taiwan. The National Health Insurance (NHI) programme, established in 1995, is a single-payer health insurance system that covers 99.9% of all residents in Taiwan. Moreover, 97% of medical providers nationwide are affiliated with the programme.¹⁷ The Longitudinal Health Insurance Database (LHID) is a nationwide representative database containing all of the original claims data for the period of 1996–2011 for 1 million NHI beneficiaries randomly sampled from the 23.22 million NHI enrollees. The availability of this population-based database has stimulated

and facilitated academic research in various scientific disciplines, particularly in the field of health research.¹⁸ In addition, the accuracy of diagnoses registered in the NHIRD has been validated using five-digit International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes, including those for diabetes and cancer, which confirms the reliability of the data source.¹⁹ In Taiwan, all patients with cancer are designated as having a catastrophic illness. For this study, we identified patients with liver cancer and catastrophic illness designations in the LHID and followed up with these patients until December 2011. ICD-9-CM and A codes were used to define liver cancer (namely, 155, 155.0, 155.1 and A095).

Study sample

This study included patients aged ≥18 years who had received a first-time diagnosis of liver cancer between 1 January 1997 and 31 December 2010. The NHIRD was used to identify the patients, and their diagnoses of cancer were confirmed using the Registry of Catastrophic Illness. Patients were excluded if they had made no insurance claims during their final year of life, were still alive during the 6 months before the end of the dataset or had missing data. A total of 4621 patients with liver cancer were enrolled in this study (figure 1).

Frequency of abdominal ultrasonography surveillance during the 2 years preceding liver cancer diagnosis

We classified the study population into two groups based on their frequency of receiving US during the 2 years preceding their liver cancer diagnosis: the <3 group (patients who had received US less than three times; n=3149) and the ≥3 group (patients who had received US three times or more; n=1472).

We classified the diseases that are indicators for ultrasonography into seven groups using their respective ICD-9-CM diagnosis codes. The seven disease groups are as follows: (1) liver-related diseases, including chronic hepatitis, cirrhosis and other liver disorders (ICD-9 codes: 571, 571.x, 572, 572.0, 573 and 573.x); (2) viral hepatitis infections (ICD-9 codes for HBV: V0261, 070.20–070.23 and 070.30–070.33; for HCV: V0262, 070.41, 070.44, 070.51 and 070.54); (3) gallbladder and biliary tract-related diseases (ICD-9 codes: 574–576); (4) abdominal pain conditions (ICD-9 codes: 789.0x, 789.4x, 789.6x and 789.9); (5) kidney–urinary–bladder (KUB) diseases (ICD-9 codes: 591, 592, 592.0, 592.1, 592.9, 593 and 593.2); (6) pancreatic diseases (ICD-9 code: 577.x); and (7) other conditions, such as hepatomegaly, splenomegaly, abdominal or pelvic mass, and ascites (ICD-9 codes: 7891, 7892, 7893x and 7895).

Definition of variables

Charlson comorbidity index (CCI) scores were calculated by examining patients’ ICD-9-CM diagnoses and procedure codes recorded in the year prior to their liver cancer diagnosis, according to the Deyo method. After referring

Figure 1 Study flowchart. ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification.

to Klabundle *et al*, we calculated CCI scores for both inpatient and outpatient claims.^{20–22}

The study protocol was reviewed and approved by the Research Ethics Committee of Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taiwan (Approval No. B10304018). Because the NHIRD contains only deidentified secondary data, the review board waived the requirement for informed consent.

Statistical analyses

In this paper, continuous variables are expressed in mean±D, and categorical variables are presented in frequency and percentage. For the univariate analysis, a two-sample t-test, Wilcoxon rank-sum test, χ^2 test and Fisher's exact test were performed to examine differences in the distribution of the continuous and categorical variables between the two groups. The survival duration (years) was defined as the duration from the day of diagnosis to the day of death. In addition, generalised additive models (GAMs) were fitted to detect the

potential non-linear effects of continuous covariates and to identify the appropriate cut-off points for discretising continuous covariates (if necessary) during the stepwise variable selection. Computationally, the VGAM function (with the default values of smoothing parameters) of the VGAM package was used to fit GAMs for the binary outcome in R.

Cox proportional hazard regression models were used to estimate the event-specific HRs and 95% CIs of all the variables listed in tables 1 and 2. Subsequently, a multivariate analysis was conducted by fitting the multiple logistic regression models (through a stepwise variable selection procedure) to identify the crucial predictors of receiving US three times or more during the 2 years preceding a liver cancer diagnosis. The goodness-of-fit (GOF) of the final logistic regression model was assessed by estimating the area under the curve (AUC; also called the c statistic), where $0 \leq c \leq 1$, and by conducting the Hosmer-Lemeshow GOF test. In practice, $c \geq 0.7$ is an acceptable level of

Table 1 Comparison of demographic characteristics between the <3 and ≥3 groups

Variable	<3 group, n (%)	≥3 group, n (%)	p Value
Total no (%)	3149 (68.1)	1472 (31.9)	
Age (years)	63.04±13.92	63.77±11.76	0.474
Gender			<0.001
Female	807 (25.6)	527 (35.8)	
Male	2342 (74.4)	945 (64.2)	
Survival*	0.51 (0.17, 1.81)	1.42 (0.48, 3.34)	<0.001
HBV	1119 (35.5)	619 (42.1)	<0.001
HCV	660 (21.0)	620 (42.1)	<0.001
Diabetes	535 (17.0)	361 (24.5)	<0.001
CKD	276 (8.8)	232 (15.8)	<0.001
CVA	535 (17.0)	297 (20.2)	0.001
Hypertension	1173 (37.2)	691 (46.9)	<0.001
Cirrhosis	2048 (65.0)	1183 (80.4)	<0.001
Employment (yes)	1873 (59.5)	891 (60.5)	0.499
Northern area in Taiwan	1063 (33.8)	467 (31.7)	0.178
Central area in Taiwan	888 (28.2)	461 (31.3)	0.031
Southern area in Taiwan	1032 (32.8)	480 (32.6)	0.920
Eastern area in Taiwan	153 (4.9)	57 (3.9)	0.150

*Survival: median (first quartile, third quartile).

CCI, Charlson comorbidity index; CKD, chronic kidney disease; CVA, cerebral vascular accident; HBV, hepatitis B virus; HCV, hepatitis C virus.

discrimination power for a fitted logistic regression model and $p > 0.05$ in the Hosmer-Lemeshow test indicates a good fit for the logistic regression model. Moreover, a variance inflation factor of ≥ 10 for continuous covariates or ≥ 2.5 for categorical covariates indicates that multicollinearity occurs among some of the covariates in a fitted logistic regression model. All statistical analyses were performed

Figure 2 Smoothing curve of the frequency of ultrasonography during the 2 years preceding liver cancer diagnosis against 5-year survival probability after adjustment (x-axis: frequency of ultrasonography during the 2 years preceding liver cancer diagnosis; y-axis: probability of 5-year survival).

using the R V.3.0.2 software (R Foundation for Statistical Computing). Statistical significance was set at $p \leq 0.05$.

RESULTS

We enrolled 4621 adult patients (3287 men and 1334 women; ratio=2.46:1) with liver cancer who died during 1997–2010. **Figure 1** depicts the study design. Specifically, we explored the association between the frequency of US during the 2 years preceding a patient's liver cancer diagnosis and that patient's 5-year survival probability. The optimal cut-off point for receiving US to ensure a higher 5-year survival probability was set at three sessions (**figure 2**).

Table 1 summarises the demographic characteristics of the study patients and indicates that those in the ≥3 group were more likely to be women ($p < 0.001$) and were more likely to have the comorbidities of viral hepatitis (HBV or HCV infection) ($p < 0.001$), cirrhosis ($p < 0.001$), diabetes ($p < 0.001$), hypertension ($p < 0.001$) or stroke ($p = 0.001$). Notably, the median survival of the ≥3 group (1.42 years) was higher than that of the <3 group (0.51 years) ($p < 0.001$). The indicators for abdominal US used in this study are summarised in **table 2**. The most frequent indicators were viral hepatitis (2580, 55.8%), gallbladder diseases (1690, 36.6%) and abdominal pain (1387,

Table 2 Ultrasonography surveillance indicators in the <3 and ≥3 groups

Variable	Total no (%)	<3 group, n (%)	≥3 group, n (%)	p Value
Viral hepatitis (HBV, HCV)	2580 (55.8)	1556 (49.4)	1024 (69.6)	<0.001
Chronic hepatitis (except HBV, HCV)	1560 (33.8)	1179 (37.4)	381 (25.9)	<0.001
Gallbladder diseases	1690 (36.6)	989 (31.4)	701 (47.6)	<0.001
Abdominal pain	1387 (30.0)	921 (29.2)	466 (31.7)	0.098
KUB diseases	928 (20.1)	524 (16.6)	404 (27.4)	<0.001
Pancreas diseases	271 (5.9)	133 (4.2)	138 (9.4)	<0.001
Others*	1780 (38.5)	1085 (34.5)	695 (47.2)	<0.001

*Hepatomegaly, splenomegaly, abdominal or pelvic mass, and ascites.

HBV, hepatitis B virus; HCV, hepatitis C virus; KUB, kidney–urinary–bladder.

Table 3 Comparison of treatment received by the <3 and ≥3 groups following ultrasonography surveillance

Variable	<3 group, n (%)	≥3 group, n (%)	p Value
PEI	200 (6.4)	244 (16.6)	<0.001
Hepatectomy	343 (10.9)	221 (15.0)	<0.001
RFA	71 (2.3)	101 (6.9)	<0.001
Liver transplantation	2 (0.1)	6 (0.4)	0.015
TACE	584 (18.5)	453 (30.8)	<0.001
Chemotherapy	1169 (37.1)	677 (46.0)	<0.001
Radiotherapy	647 (20.5)	334 (22.7)	0.097
Five-year survival probability	7.7%	14.4%	<0.001

PEI, percutaneous ethanol injection; RFA, radiofrequency ablation; TACE, transcatheter arterial chemoembolisation.

30.0%). In this study, all indicators, except for abdominal pain ($p=0.098$), were significantly higher in the ≥3 group than in the <3 group.

Compared with the <3 group, significantly higher proportions of the ≥3 group received all possible treatments for liver cancer, except for radiotherapy ($p=0.097$); the ≥3 group also had significantly higher 5-year survival probability than did the <3 group (14.4% vs 7.7%, respectively; $p<0.001$) (table 3). From the multivariate Cox proportional hazard regression model, the positive significant predictors of death were male sex (HR 1.14, 95% CI 1.07 to 1.22), older age (HR 1.02, 95% CI 1.01 to 1.03), diabetes (HR 1.13, 95% CI 1.04 to 1.22) and a high CCI score (HR 1.07, 95% CI 1.05 to 1.08). Conversely, the negative significant predictors of death were hypertension (HR 0.83, 95% CI 0.78 to 0.89), stroke (HR 0.78, 95% CI 0.72 to 0.84), chronic kidney diseases (CKDs) (HR 0.84, 95% CI 0.74 to 0.92), viral hepatitis (HBV or HCV infection) (HR 0.79, 95% CI 0.72 to 0.88) and receiving US three times or more during the 2 years preceding liver cancer diagnosis (HR 0.80, 95% CI 0.75 to 0.85).

The significant indicators for US among the patients in this study included KUB diseases (HR 0.92, 95% CI 0.86 to 0.995), gallbladder diseases (HR 0.90, 95% CI 0.85 to 0.96), chronic hepatitis (except for HBV or HCV infection) (HR 0.90, 95% CI 0.81 to 0.999) and pancreatic diseases (HR 0.80, 95% CI 0.71 to 0.91). Moreover, the primary complications of liver cancer were upper gastrointestinal bleeding (gastric ulcer or duodenal ulcer) (HR 0.92, 95% CI 0.86 to 0.98) and oesophageal variceal bleeding (HR 0.90, 95% CI 0.83 to 0.97), and the main treatments that the patients received for liver cancer were transcatheter arterial chemoembolisation (TACE) (HR 0.82, 95% CI 0.76 to 0.89), radiotherapy (HR 0.81, 95% CI 0.75 to 0.87), radiofrequency ablation (RFA) (HR 0.79, 95% CI 0.68 to 0.93), chemotherapy (HR 0.71, 95% CI 0.67 to 0.76), resection (HR 0.67, 95% CI 0.61 to 0.73) and percutaneous ethanol injection (PEI) (HR 0.64, 95% CI 0.57 to 0.70). Furthermore, the demographic

factors significantly linked with greater US frequency were employment (HR 0.89, 95% CI 0.83 to 0.95) and living in Northern Taiwan (HR 0.91, 95% CI 0.85 to 0.97) (table 4).

Survival probability was significantly higher in the ≥3 group than in the <3 group ($p<0.001$; figure 3). According to the multivariate logistic regression model, the significant positive predictors for survival in the ≥3 group were viral hepatitis (HBV or HCV infection) (OR 3.66, 95% CI 2.76 to 4.85), gallbladder diseases (OR 1.82, 95% CI 1.59 to 2.09), KUB diseases (OR 1.80, 95% CI 1.53 to 2.11), pancreatic diseases (OR 1.79, 95% CI 1.37 to 2.34), chronic hepatitis (except for viral hepatitis; OR 1.75, 95% CI 1.31 to 2.34), CKDs (OR 1.60, 95% CI 1.30 to 1.96), diabetes (OR 1.56, 95% CI 1.31 to 1.86), US indications of other conditions (OR 1.47, 95% CI 1.29 to 1.69), hypertension (OR 1.17, 95% CI 1.01 to 1.34) and living in Central Taiwan (OR 1.16, 95% CI 1.01 to 1.34). Conversely, the significant negative predictors for survival in the ≥3 group were male sex (OR 0.60, 95% CI 0.52 to 0.69) and the US indication of abdominal pain (OR 0.81, 95% CI 0.70 to 0.93) (table 5).

The results of the Hosmer-Lemeshow test indicated a good fit ($p=0.156$) and that the AUC was acceptable (0.707, 95% CI 0.691 to 0.723) (figure 4).

DISCUSSION

In this study, we found that patients with liver cancer who had received US three times or more during the 2 years preceding their liver cancer diagnosis exhibited high 5-year survival compared with those who had received US less than three times during that same period (14.4% vs 7.7%). We also determined that, compared with the <3 group, higher proportions of the ≥3 group received treatment for early-stage liver cancer (eg, PEI, hepatectomy, RFA or liver transplantation). As illustrated in figure 2, there was a linear dose-response relationship between US frequency and the logit of 5-year survival probability; a similar result was also reported in a previous study.²³ Further cost-effectiveness analyses are needed to justify recommending three or more sessions of US to people at a high risk of liver cancer diagnosis or to the general population in an area with a high incidence of liver cancer.

According to one previous trial, biannual US for patients with HBV infection reduces hepatocellular carcinoma mortality by 37%.²⁴ Another cohort study reported that patients with viral hepatitis who receive routine US exhibit higher 5-year survival than do those who did not receive routine US (31.84% vs 20.67%, respectively).²⁵ Other scholars have indicated that certain populations at a high risk for developing hepatocellular carcinoma benefit from more intensive US.^{26–30} One trial study revealed that early-stage hepatocellular carcinoma was more likely to be detected in patients with viral hepatitis who received US at 4-month intervals than in those who received US at 12-month intervals; however, patients' overall survival was

Table 4 Results of the multivariate Cox proportional hazard regression of predictors of death among patients with liver cancer

Variable	HR	95% CI	p Value
Male	1.14	1.07 to 1.22	<0.001
Age (hepatocellular cancer diagnosis) per 5 years	1.02	1.01 to 1.03	0.002
Diabetes	1.13	1.04 to 1.22	0.004
Hypertension	0.83	0.78 to 0.89	<0.001
CVA	0.78	0.72 to 0.84	<0.001
CKD	0.84	0.74 to 0.92	<0.001
Viral hepatitis (HBV, HCV)	0.79	0.72 to 0.88	<0.001
CCI (per 1 score)	1.07	1.05 to 1.08	<0.001
US indications			
Three times or more US	0.80	0.75 to 0.85	<0.001
KUB diseases	0.92	0.86 to 0.995	0.037
Gallbladder diseases	0.90	0.85 to 0.96	0.001
Chronic liver diseases (except HBV, HCV)	0.90	0.81 to 0.999	0.047
Pancreas diseases	0.80	0.71 to 0.91	<0.001
Complication of liver cancer			
UGI bleeding (GU, DU)	0.92	0.86 to 0.98	0.009
EV bleeding	0.90	0.83 to 0.97	0.008
Treatments			
TACE	0.82	0.76 to 0.89	<0.001
Radiotherapy	0.81	0.75 to 0.87	<0.001
RFA	0.79	0.68 to 0.93	0.004
Chemotherapy	0.71	0.67 to 0.76	<0.001
hepatectomy	0.67	0.61 to 0.73	<0.001
PEI	0.64	0.57 to 0.70	<0.001
Background			
Employment	0.89	0.83 to 0.95	<0.001
Northern area in Taiwan	0.91	0.85 to 0.97	0.003

CCI, Charlson comorbidity index; CKD, chronic kidney disease; CVA, cerebral vascular accident; DU, duodenal ulcer; EV, esophageal varices; GU, gastric ulcer; HBV, hepatitis B virus; HCV, hepatitis C virus; KUB, kidney–urinary–bladder; PEI, percutaneous ethanol injection; RFA, radiofrequency ablation; TACE, transcatheter arterial chemoembolisation; UGI, upper gastrointestinal tract; US, ultrasonography surveillance.

not different at the 4-year follow-up.³¹ In another systemic review, the effects of hepatocellular carcinoma screening on mortality in patients with chronic hepatitis were found to be uncertain.¹⁶

Figure 3 Survival curves of the <3 group and ≥3 group.

In short, receiving US at a high frequency has no confirmed beneficial effect on the 5-year survival probability of patients with hepatocellular carcinoma. This finding may be because the early detection of liver cancer improves the rate of curative treatments. However, the prognosis of patients with liver cancer is not solely related to the tumour stage,³² and regular follow-up for possible recurrence and treatment is vital. Although the survival of patients with liver cancer has improved overall in the past decade, physicians caring for at-risk patients should provide regular high-quality screening, including ultrasonography.¹³

Although advanced diagnostic techniques, such as dynamic multiphasic multidetector-row CT and MRI, are the standard diagnostic methods for the non-invasive diagnosis of liver cancer, ultrasonography still plays a crucial role in liver cancer surveillance.³³ In Taiwan,

Table 5 Results of the multivariate logistic regression of the predictors for receiving ultrasonography surveillance three times or more during the 2 years preceding a liver cancer diagnosis

Variables	OR	95% CI	p Value
Male	0.60	0.52 to 0.69	<0.001
Diabetes	1.56	1.31 to 1.86	<0.001
Hypertension	1.17	1.01 to 1.34	0.03
CKD	1.60	1.30 to 1.96	<0.001
US indications			
Viral hepatitis (HBV or HCV infection)	3.66	2.76 to 4.85	<0.001
Gallbladder diseases	1.82	1.59 to 2.09	<0.001
KUB diseases	1.80	1.53 to 2.11	<0.001
Pancreas diseases	1.79	1.37 to 2.34	<0.001
Chronic hepatitis except viral hepatitis	1.75	1.31 to 2.34	<0.001
Other*	1.47	1.29 to 1.69	<0.001
Abdominal pain	0.81	0.70 to 0.93	0.004
Central area in Taiwan	1.16	1.01 to 1.34	0.04

*Includes hepatomegaly, splenomegaly, abdominal or pelvic mass, and ascites.

CKD, chronic kidney disease; HBV, hepatitis B virus; HCV, hepatitis C virus; KUB, kidney–urinary–bladder; US, ultrasonography surveillance.

the recommended intervals for US screening is 6 months for patients with viral hepatitis infection and 3 months for patients with cirrhosis. Ultrasonography can be performed in hospital and clinics, if indicated, and the cost of each ultrasonography screening (US\$23.1) is covered by the NHI programme.

In the present study, we found that patients with chronic hepatitis (both HBV and HCV, and non-HBV and non-HCV infections), diabetes, CKDs, cerebral vascular accident (CVA), hypertension, gallbladder diseases, KUB diseases, pancreatic diseases and other US-indicating

Figure 4 Receiver operating characteristic curves of the predictors for receiving ultrasonography three or more times during the 2 years preceding liver cancer diagnosis. AUC, area under the curve.

conditions (ie, hepatomegaly, splenomegaly, abdominal or pelvic mass, and ascites) were more likely to receive US three times or more during the 2 years preceding their liver cancer diagnosis. One reason that patients with diabetes in this study were more likely to receive US three times or more might be because these patients are at a high risk of primary liver cancer.^{34–36} Notably, the association between diabetes and liver cancer is significantly strengthened when the history of diabetes is longer than 10 years.^{37,38} Some studies have also suggested that insulin might enhance the risk of hepatocellular cancer, whereas certain oral glucose-lowering medications and statins may decrease the risk of hepatocellular cancer.^{39,40}

Similarly, patients with CKD in this study were more likely to receive US three times or more, most likely because of the close link between kidney diseases and cancer.⁴¹ Indeed, cancer has become increasingly recognised as a complication and a major cause of morbidity and mortality in the CKD population.⁴² Finally, the reason that patients with CVA, hypertension, gallbladder diseases, KUB diseases, pancreatic diseases or other US-indicating conditions in this study were more likely to receive US three times or more is probably because patients with more comorbidities and physician visits are more likely to undergo more laboratory tests and imaging studies, including US, if they experience any discomfort.

The chances of developing NAFLD are enhanced by type 2 diabetes, arterial hypertension, obesity, metabolic syndrome, mixed hyperlipidaemia and familial hypobeta-lipoproteinaemia, all of which are the chief metabolic modifiers of NAFLD risk.^{43–45} In this study, NAFLD was included in the group of liver-related diseases alongside chronic hepatitis, cirrhosis and other liver disorders. However, the imprecise classification for NAFLD is one of the claims-data-related limitations of this study. Instead, we classified the diseases that are the indicators for US into seven groups; patients with these indicators easily received US due to its widespread availability in Taiwan. Another limitation of this study is that baseline data were not recorded in the claims data and thus could not be investigated. For example, the underlying causes of pancreatic disease include alcohol abuse, biliary disease, hyperlipidaemia and other risk factors, aetiologies or idiopathic diseases⁴⁶; however, it is unknown whether patients in the present study who had pancreatic disease were also diagnosed with any of these baseline factors or diseases.

As noted earlier, higher proportions of the ≥ 3 group received treatment for early-stage liver cancer, such as PEI, hepatectomy, RFA or liver transplantation, than did the < 3 group. Such treatments have similarly been reported as therapies for early-stage hepatocellular carcinoma in previous studies.^{47–50} We also determined that higher proportions of the ≥ 3 group received TACE compared with the < 3 group, although the therapeutic effects of TACE for early-stage hepatocellular carcinoma are unclear.⁵¹

One previous study reported that mass screening for liver cancer by using US in high-endemic regions,

including Taiwan, is cost-effective and recommended.⁵² In this study, the significant positive predictors for survival in the ≥ 3 group were viral hepatitis, gallbladder diseases, KUB diseases, pancreatic diseases, chronic hepatitis (except viral infections), diabetes, US indications of other conditions, hypertension and living in Central Taiwan. By contrast, the significant negative predictors for survival in the ≥ 3 group were male sex and the US indication of abdominal pain. The reason that these factors are negative predictors might be because men are less likely to seek medical attention than are women,⁵³ and because after seeking medical attention for one abdominal pain event, patients do not return for subsequent follow-up, respectively. However, we could not confirm the precise reason that these factors are negative predictors because such information is not available from the claims data; this is another limitation of this study. Furthermore, although the patients with these negative predictors were more likely to die of liver cancer, official cause of death is not recorded in the claims data, and such causal links could not be confirmed in this study.

Finally, this was an observational cohort study, and its validity may be jeopardised by confounding variables, such as cancer stage, body mass index, smoking and alcohol consumption, that were not included in the dataset and thus were not measured. We therefore suggest that randomised clinical trials be conducted before the conclusions of the present study are applied to clinical practice in Taiwan and elsewhere.

CONCLUSIONS

The 5-year survival probability of patients with liver cancer may improve if they receive abdominal US three times or more during the 2 years preceding their liver cancer diagnosis. Additional studies should prospectively investigate whether abdominal US can be used to identify early-stage liver cancer and examine whether further treatment with regular follow-up improves survival.

Contributors JKC, LCW and YHK designed, conducted and drafted the manuscript. JKC analysed the data. All authors contributed to the manuscript, revised drafts critically for important intellectual content and read and approved the final manuscript.

Funding JKC received research grants from Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation (DTCRD105 (2)E22). The funding source had no involvement in the study design; collection, analysis and interpretation of data; writing of the report; or decision to submit the article for publication.

Disclaimer This study is based in part on data from the National Health Insurance Research Database, provided by the Bureau of National Health Insurance of the Department of Health and managed by the National Health Research Institutes. The interpretations and conclusions contained herein do not represent those of the Bureau of National Health Insurance, Department of Health or National Health Research Institutes.

Competing interests None declared.

Ethics approval The study protocol was reviewed and approved by the Research Ethics Committee of Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taiwan (approval no B10304018).

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Extra data can be accessed via the Dryad data repository at <http://datadryad.org/> with the doi:10.5061/dryad.r1m19.

Open Access This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <http://creativecommons.org/licenses/by/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

1. GLOBOCAN. Estimated cancer incidence, mortality and prevalence worldwide. 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. (accessed 6 Jul 2016).
2. Ministry of Health and Welfare. Statistics of causes of death. 2016;1 http://www.mohw.gov.tw/cht/DOS/Statistic.aspx?f_list_no=312&fod_list_no=2747.
3. Parikh S, Hyman D. Hepatocellular cancer: a guide for the internist. *Am J Med* 2007;120:194–202.
4. Gomaa AI, Khan SA, Toledano MB, et al. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. *World J Gastroenterol* 2008;14:4300–8.
5. Chen DS, Hsu NH, Sung JL, et al. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. *JAMA* 1987;257:2597–603.
6. Liu CJ, Kao JH. Hepatitis B virus-related hepatocellular carcinoma: epidemiology and pathogenic role of viral factors. *J Chin Med Assoc* 2007;70:141–5.
7. Ni YH, Chang MH, Huang LM, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. *Ann Intern Med* 2001;135:796–800.
8. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. *N Engl J Med* 1997;336:1855–9.
9. Wait S, Chen DS. Towards the eradication of hepatitis B in Taiwan. *Kaohsiung J Med Sci* 2012;28:1–9.
10. Chiang C-J, W-C L, Yang Y-W, et al. Incidence and survival of adult cancer 30 patients in Taiwan, 2002–2012. *J Formos Med Assoc*, 2015. <http://dx.doi.org/10.1016/j.jfma.2015.10.011>.
11. Lok AS, Sterling RK, Everhart JE, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. *Gastroenterology* 2010;138:493–502.
12. Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. *Aliment Pharmacol Ther* 2009;30:37–47.
13. Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. *Hepatology* 2011;53:1020–2.
14. European Association for the Study of the Liver/European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol* 2012;56:908–43.
15. El-Serag HB, Davila JA. Surveillance for hepatocellular carcinoma: in whom and how? *Therap Adv Gastroenterol* 2011;4:5–10.
16. Kansagara D, Papak J, Pasha AS, et al. Screening for hepatocellular carcinoma in chronic liver disease: a systematic review. *Ann Intern Med* 2014;161:261–9.
17. National Health Insurance Research Database (NHIRD), Taiwan. http://nhird.nhri.org.tw/date_01.html (accessed 22 May 2016).
18. Chen Y-C, Yeh H-Y, Wu J-C, et al. Taiwan's National Health Insurance Research Database: administrative health care database as study object in bibliometrics. *Scientometrics* 2011;86:365–80.
19. Lin CC, Lai MS, Syu CY, et al. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. *J Formos Med Assoc* 2005;104:157–63.
20. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987;40:373–83.
21. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. *J Clin Epidemiol* 1992;45:613–9.
22. Klabunde CN, Potosky AL, Legler JM, et al. Development of a comorbidity index using physician claims data. *J Clin Epidemiol* 2000;53:1258–67.
23. Wu CY, Hsu YC, Ho HJ, Cy W, HJ H, et al. Association between ultrasonography screening and mortality in patients with

- hepatocellular carcinoma: a nationwide cohort study. *Gut* 2016;65:693–701.
24. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. *J Cancer Res Clin Oncol* 2004;130:417–22.
 25. Thein HH, Campitelli MA, Yeung LT, *et al.* Improved survival in patients with viral hepatitis-induced hepatocellular carcinoma undergoing recommended abdominal ultrasound surveillance in Ontario: a population-based retrospective cohort study. *PLoS One* 2015;10:e0138907.
 26. Santi V, Trevisani F, Gramenzi A, *et al.* Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. *J Hepatol* 2010;53:291–7.
 27. Santi V, Buccione D, Di Micoli A, *et al.* The changing scenario of hepatocellular carcinoma over the last two decades in Italy. *J Hepatol* 2012;56:397–405.
 28. Giannini EG, Cucchetti A, Erroi V, *et al.* Surveillance for early diagnosis of hepatocellular carcinoma: how best to do it? *World J Gastroenterol* 2013;19:8808–21.
 29. Del Poggio P, Olmi S, Ciccarese F, *et al.* Italian Liver Cancer (ITA.LI.CA) Group. Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis. *Clin Gastroenterol Hepatol* 2014;12:1927–33.
 30. Cucchetti A, Trevisani F, Pecorelli A, *et al.* Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma. *J Hepatol* 2014;61:333–41.
 31. Wang JH, Chang KC, Kee KM, *et al.* Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community. *Am J Gastroenterol* 2013;108:416–24.
 32. Greten TF, Papendorf F, Bleck JS, *et al.* Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. *Br J Cancer* 2005;92:1862–8.
 33. Lee JM, Yoon JH, Kim KW. Diagnosis of hepatocellular carcinoma: newer radiological tools. *Semin Oncol* 2012;39:399–409.
 34. Adami HO, Chow WH, Nyrén O, *et al.* Excess risk of primary liver cancer in patients with diabetes mellitus. *J Natl Cancer Inst* 1996;88:1472–7.
 35. La Vecchia C, Negri E, Decarli A, *et al.* Diabetes mellitus and the risk of primary liver cancer. *Int J Cancer* 1997;73:204–7.
 36. Fujino Y, Mizoue T, Tokui N, *et al.* Prospective study of diabetes mellitus and liver cancer in Japan. *Diabetes Metab Res Rev* 2001;17:374–9.
 37. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. *Gastroenterology* 2004;126:460–8.
 38. Yu MC, Tong MJ, Govindarajan S, *et al.* Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California. *J Natl Cancer Inst* 1991;83:1820–6.
 39. Lonardo A, Ballestri S, Targher G, *et al.* Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. *Expert Rev Gastroenterol Hepatol* 2015;9:629–50.
 40. Lonardo A, Loria P. Potential for statins in the chemoprevention and management of hepatocellular carcinoma. *J Gastroenterol Hepatol* 2012;27:1654–64.
 41. Magee C. Kidney disease and death from cancer. *Am J Kidney Dis* 2014;63:7–9.
 42. Izzedine H, Perazella MA. Onco-nephrology: an appraisal of the cancer and chronic kidney disease links. *Nephrol Dial Transplant* 2015;30:1979–88.
 43. Non-alcoholic Fatty Liver Disease Study Group, Lonardo A, Bellentani S, *et al.* Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. *Dig Liver Dis* 2015;47:997–1006.
 44. Rinaldi L, Nascimbeni F, Giordano M, *et al.* Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis. *World J Gastroenterol* 2017;23:1458–68.
 45. Piscaglia F, Svegliati-Baroni G, Barchetti A, *et al.* Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. *Hepatology* 2016;63:827–38.
 46. Chen CH, Dai CY, Hou NJ, *et al.* Etiology, severity and recurrence of acute pancreatitis in southern Taiwan. *J Formos Med Assoc* 2006;105:550–5.
 47. Bruix J, Sherman M. Practice Guidelines Committee AASLD. Management of hepatocellular carcinoma. *Hepatology* 2005;42:1208–36.
 48. Makuuchi M, Kokudo N, Arii S, *et al.* Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. *Hepatol Res* 2008;38:37–51.
 49. Llovet JM, Di Bisceglie AM, Bruix J, *et al.* Design and endpoints of clinical trials in hepatocellular carcinoma. *J Natl Cancer Inst* 2008;100:698–711.
 50. Takayama T, Makuuchi M, Kojiro M, *et al.* Early hepatocellular carcinoma: pathology, imaging, and therapy. *Ann Surg Oncol* 2008;15:972–8.
 51. Ye SL, Takayama T, Geschwind J, *et al.* Current approaches to the treatment of early hepatocellular carcinoma. *Oncologist* 2010;15(Suppl 4):34–41.
 52. Kuo MJ, Chen HH, Chen CL, *et al.* Cost-effectiveness analysis of population-based screening of hepatocellular carcinoma: comparing ultrasonography with two-stage screening. *World J Gastroenterol* 2016;22:3460–70.
 53. Bertakis KD, Azari R, Helms LJ, *et al.* Gender differences in the utilization of health care services. *J Fam Pract* 2000;49:147–52.